David Dunner
Psychiatry · Mercer Island, WANPI 1023188463
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.2%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Johnson & Johnson accounts for 66.6% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2019 at $51,333 and has fallen 96.6% since, to $1,770 in 2025. Among psychiatry clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 543 payments — averaging $145.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$53K
- Janssen Scientific Affairs, LLC$16K
- Livanova USA, Inc.$3K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- AbbVie$1K
- Otsuka America Pharmaceutical, Inc.$846
- plus $4K from 19 others
Across 400 payments — averaging $1492.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Livanova USA, Inc.$597K
What the payments were for
- Consulting fees$17,36522%
- Speaking & faculty fees$44,50056%
- Travel & lodging$5,2637%
- Food & beverage$11,88815%
- Education$1420%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 99 | $52,682 |
| Janssen Scientific Affairs, LLC | 18 | $15,845 |
| Livanova USA, Inc. | 33 | $3,294 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 90 | $1,580 |
| AbbVie(2 entities) | 70 | $1,215 |
| Otsuka America Pharmaceutical, Inc. | 57 | $846 |
| Teva Pharmaceuticals USA, Inc. | 37 | $761 |
| Neurocrine Biosciences, Inc. | 23 | $623 |
| Lundbeck LLC | 29 | $536 |
| Alkermes, Inc. | 11 | $264 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $245 |
| Axsome Therapeutics, Inc. | 10 | $233 |
| Idorsia Pharmaceuticals US Inc | 11 | $205 |
| Vanda Pharmaceuticals Inc. | 10 | $177 |
| Avanir Pharmaceuticals, Inc. | 8 | $164 |
| Neuronetics, Inc. | 4 | $95 |
| Alfasigma USA, Inc. | 5 | $74 |
| Sunovion Pharmaceuticals Inc. | 5 | $73 |
| Ironshore Pharmaceuticals Inc. | 4 | $56 |
| E.r. Squibb & Sons, L.L.C. | 2 | $53 |
| Vertical Pharmaceuticals, LLC | 2 | $40 |
| Merck | 2 | $38 |
| Tris Pharma Inc | 1 | $23 |
| Noven Therapeutics, LLC | 1 | $21 |
| Collegium Pharmaceutical, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$66,464
- INVEGA SUSTENNA$3,133
- Ponvory$3,133
- VNS Therapy$1,251
- VNS Therapy Symmetry Model 8103 Generator$877
- VNS - Symmetry$153
- INGREZZA$129
How this compares
$79,159 in reported general payments places this provider in the 95th percentile of 576 psychiatry providers in Washington.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CaplytaLumateperone Tosylate | 13 | $24,533 |
| Quetiapine Fumarate | 22 | $2,054 |
| Bupropion XlBupropion Hcl | 27 | $1,192 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 11 | $761 |
| Lamotrigine | 13 | $264 |
| Temazepam | 13 | $43 |
| Lorazepam | 11 | $28 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,580 | $24,53313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 576 psychiatry providers in Washington.
Other psychiatry in Mercer Island
- Cara ErkutMercer Island$14K
- Christina DemopulosMercer Island$9K
- Ryan FugateMercer Island$4K
- Jeffrey HansenVancouver$2.8M
- Chester RobachinskiSeattle$1.1M
- Larry BornsteinEverett$663K
- Matthew BogoyasYakima$500K
- Pablo ProanoSeattle$112K
- Jesse McClellandSeattle$39K
- Douglas WornellFox Island$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.